Abbott Laboratories (NYSE:ABT) Shares Sold by Mark Sheptoff Financial Planning LLC

Mark Sheptoff Financial Planning LLC reduced its holdings in shares of Abbott Laboratories (NYSE:ABT) by 1.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,852 shares of the healthcare product maker’s stock after selling 600 shares during the quarter. Abbott Laboratories makes up 3.0% of Mark Sheptoff Financial Planning LLC’s investment portfolio, making the stock its 8th largest position. Mark Sheptoff Financial Planning LLC’s holdings in Abbott Laboratories were worth $4,937,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Signature Resources Capital Management LLC purchased a new stake in shares of Abbott Laboratories in the fourth quarter valued at $29,000. Rise Advisors LLC acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth about $37,000. Stuart Chaussee & Associates Inc. grew its holdings in shares of Abbott Laboratories by 236.0% during the fourth quarter. Stuart Chaussee & Associates Inc. now owns 336 shares of the healthcare product maker’s stock worth $37,000 after buying an additional 236 shares in the last quarter. Cornerstone Planning Group LLC raised its position in shares of Abbott Laboratories by 79.4% in the third quarter. Cornerstone Planning Group LLC now owns 454 shares of the healthcare product maker’s stock valued at $44,000 after buying an additional 201 shares during the last quarter. Finally, Private Wealth Management Group LLC purchased a new position in shares of Abbott Laboratories during the fourth quarter valued at approximately $44,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on ABT shares. Citigroup cut their price target on Abbott Laboratories from $128.00 to $119.00 and set a “buy” rating for the company in a report on Wednesday. Raymond James reiterated a “buy” rating and set a $124.00 target price on shares of Abbott Laboratories in a research report on Wednesday, April 24th. Barclays lowered their price target on Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating for the company in a report on Monday, April 22nd. Evercore ISI increased their price objective on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Finally, Royal Bank of Canada dropped their price target on shares of Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating for the company in a research report on Thursday, April 18th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $120.60.

Abbott Laboratories Stock Down 0.6 %

NYSE:ABT traded down $0.67 during mid-day trading on Thursday, reaching $104.15. The stock had a trading volume of 3,280,939 shares, compared to its average volume of 5,625,255. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.11. The company has a market capitalization of $181.18 billion, a price-to-earnings ratio of 32.61, a price-to-earnings-growth ratio of 2.48 and a beta of 0.76. Abbott Laboratories has a 1-year low of $89.67 and a 1-year high of $121.64. The stock’s 50 day simple moving average is $108.59 and its two-hundred day simple moving average is $109.50.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, April 17th. The healthcare product maker reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.96 by $0.02. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.96%. The business had revenue of $9.96 billion during the quarter, compared to the consensus estimate of $9.88 billion. During the same period in the previous year, the business earned $1.03 EPS. The business’s quarterly revenue was up 2.2% on a year-over-year basis. Equities analysts anticipate that Abbott Laboratories will post 4.62 EPS for the current year.

Insider Buying and Selling at Abbott Laboratories

In related news, EVP Andrea F. Wainer sold 12,500 shares of Abbott Laboratories stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the sale, the executive vice president now directly owns 78,704 shares in the company, valued at $9,444,480. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, EVP Daniel Gesua Sive Salvadori sold 963 shares of Abbott Laboratories stock in a transaction on Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $114,115.50. Following the transaction, the executive vice president now directly owns 125,697 shares in the company, valued at approximately $14,895,094.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Andrea F. Wainer sold 12,500 shares of the stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $120.00, for a total value of $1,500,000.00. Following the completion of the transaction, the executive vice president now owns 78,704 shares of the company’s stock, valued at approximately $9,444,480. The disclosure for this sale can be found here. Insiders have sold 46,884 shares of company stock valued at $5,153,916 in the last quarter. Corporate insiders own 1.10% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.